bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIAF bioAffinity Technologies, Inc.

Closed 11-05 16:00:00 EST

1.34

-0.04

-2.90%

盘后1.34

+0.000.00%

16:56 EST

High1.40	Low1.32	Vol38.93K
Open1.36	D1 Closing1.38	Amplitude5.80%
Mkt Cap18.08M	Tradable Cap11.67M	Total Shares13.49M
T/O52.50K	T/O Rate0.45%	Tradable Shares8.71M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BIAF","market":"US","secType":"STK","nameCN":"bioAffinity Technologies, Inc.","latestPrice":1.34,"timestamp":1730840400000,"preClose":1.38,"halted":0,"volume":38934,"hourTrading":{"tag":"盘后","latestPrice":1.34,"preClose":1.34,"latestTime":"16:56 EST","volume":1,"amount":1.34,"timestamp":1730843775609},"delay":0,"floatShares":8708600,"shares":13490300,"eps":-0.888142,"marketStatus":"Closed","change":-0.04,"latestTime":"11-05 16:00:00 EST","open":1.36,"high":1.4,"low":1.32,"amount":52504.6843,"amplitude":0.057971,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.888142,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1730883600000},"marketStatusCode":5,"adr":0,"listingDate":1662004800000,"exchange":"NASDAQ","adjPreClose":1.38,"preHourTrading":{"tag":"盘前","latestPrice":1.3799,"preClose":1.38,"latestTime":"09:09 EST","volume":1091,"amount":1499.5309505,"timestamp":1730815750666},"postHourTrading":{"tag":"盘后","latestPrice":1.34,"preClose":1.34,"latestTime":"16:56 EST","volume":1,"amount":1.34,"timestamp":1730843775609},"volumeRatio":0.436443},"requestUrl":"/m/hq/s/BIAF/tweets","defaultTab":"tweets","newsList":[{"id":"2480199589","title":"BRIEF-BioAffinity Technologies Appoints New Chief Science Officer To Spearhead Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2480199589","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480199589?lang=en_us&edition=fundamental","pubTime":"2024-11-04 22:32","pubTimestamp":1730730776,"startTime":"0","endTime":"0","summary":"Nov 4 (Reuters) - bioAffinity Technologies Inc   :   * BIOAFFINITY TECHNOLOGIES APPOINTS NEW CHIEF SCIENCE OFFICER TO SPEARHEAD PRODUCT DEVELOPMENTSource text:    Further company coverage:    (Reuters.Briefs@thomsonreuters.com)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2480004300","title":"BioAffinity Technologies appoints William Bauta, Ph.D. Chief Science Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2480004300","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480004300?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:15","pubTimestamp":1730726150,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (BIAF) announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-appoints-william-bauta-ph-d-chief-science-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-appoints-william-bauta-ph-d-chief-science-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2480307080","title":"bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2480307080","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480307080?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:00","pubTimestamp":1730725204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nTUA6KCG94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIAFW","BIAF"],"gpt_icon":0},{"id":"2480588187","title":"bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2480588187","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480588187?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:00","pubTimestamp":1730725200,"startTime":"0","endTime":"0","summary":"Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel. Dr. Bauta is responsible for multiple Company inventions and patents supporting bioAffinity’s diagnostic and therapeutic advancements, including improvements to optimize CyPath Lung, the Company’s noninvasive test to detect early-stage lung cancer, that both improved performance and cut costs. His discoveries have expanded the Company’s patent portfolio and added to a growing list of publications. In addition to bioAffinity patents on which he is a named inventor, he holds multiple healthcare-related patents and has published in more than a dozen scientific journals, including the journal Science.CyPath Lung uses proprietary advanced flow cytometry and artificial intellig","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ItQNjwTTpvwFz.E3ehvRPQ--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a8127d65ac48654886d55d2de9741a0a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ItQNjwTTpvwFz.E3ehvRPQ--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a8127d65ac48654886d55d2de9741a0a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-appoints-chief-science-130000876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIAF","BK4139","BIAFW"],"gpt_icon":0},{"id":"2479995782","title":"bioAffinity Technologies Secures Japanese Patent for Lung Cancer Diagnostic Method","url":"https://stock-news.laohu8.com/highlight/detail?id=2479995782","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479995782?lang=en_us&edition=fundamental","pubTime":"2024-10-30 22:42","pubTimestamp":1730299352,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies  said Wednesday it received a Japanese patent for its CyPath Lung diagnostic test method, which predicts lung cancer risk.The patent expands bioAffinity's portfolio to 17 granted patents, the company said.Shares of bioAffinity rose 2.7% in recent trading.Price: 1.34, Change: +0.03, Percent Change: +2.69","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2479920604","title":"bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung","url":"https://stock-news.laohu8.com/highlight/detail?id=2479920604","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479920604?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:00","pubTimestamp":1730289600,"startTime":"0","endTime":"0","summary":"SAN ANTONIO, October 30, 2024----bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Japan Patent Office has issued a Certificate of Grant of Patent to bioAffinity Technologies for the method of predicting the likelihood of lung cancer used by the CyPath Lung diagnostic test for early-stage lung cancer.bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test  by Precision Pathology Laboratory","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/RFrWoB6BVo4KfZVjkxVDJw--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/08136d77632d30ff54df7c3e7d867cb9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/RFrWoB6BVo4KfZVjkxVDJw--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/08136d77632d30ff54df7c3e7d867cb9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-announces-award-japanese-120000732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIAF","BIAFW"],"gpt_icon":0},{"id":"2477889227","title":"BioAffinity Technologies announces closing of $2.6M registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2477889227","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477889227?lang=en_us&edition=fundamental","pubTime":"2024-10-22 02:22","pubTimestamp":1729534964,"startTime":"0","endTime":"0","summary":"BioAffinity Technologies (BIAF) announced it has closed its previously announced registered direct offering with institutional investors for the pu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-announces-closing-of-2-6m-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-announces-closing-of-2-6m-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2477867015","title":"Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2477867015","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477867015?lang=en_us&edition=fundamental","pubTime":"2024-10-21 23:39","pubTimestamp":1729525141,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nTUA4KMW72:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2477860246","title":"WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2477860246","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477860246?lang=en_us&edition=fundamental","pubTime":"2024-10-21 23:39","pubTimestamp":1729525140,"startTime":"0","endTime":"0","summary":"JERSEY CITY, N.J., Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc.,a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 2,048,294 shares  of common stock at a price of $1.30 per share and concurrent private placement of common warrants  to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share for gross proceeds of $2,662,782 before deducting placement agent fees and other offering expenses payable by the Company. The Warrants are initially exercisable on the date that the Company's stockholders approve the exercise of the Warrants and the issuance of the shares upon exercise thereof and will expire five years from the date of such approval.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7OV4tyxQqPwRvFvbutrDEA--~B/aD0xODg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/08d6b078574aa4a530f8d5620e223fd7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7OV4tyxQqPwRvFvbutrDEA--~B/aD0xODg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/08d6b078574aa4a530f8d5620e223fd7"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/wallachbeth-capital-announces-closing-bioaffinity-153900722.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wallachbeth-capital-announces-closing-bioaffinity-153900722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIAF","BK4139","BIAFW"],"gpt_icon":0},{"id":"2477861069","title":"bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2477861069","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477861069?lang=en_us&edition=fundamental","pubTime":"2024-10-21 22:45","pubTimestamp":1729521900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nTUA1VT1PT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BIAFW","BK4139"],"gpt_icon":0},{"id":"2476292726","title":"Wallachbeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2476292726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476292726?lang=en_us&edition=fundamental","pubTime":"2024-10-19 02:57","pubTimestamp":1729277862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241018:nTUAC96HQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2476260223","title":"BioAffinity Technologies Down 25% on Stock Sale, Warrant Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2476260223","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476260223?lang=en_us&edition=fundamental","pubTime":"2024-10-19 01:16","pubTimestamp":1729271760,"startTime":"0","endTime":"0","summary":"BioAffinity Technologies shares declined after the company announced a $2.66 million registered direct offering of stock and a concurrent private placement of warrants.Shares were down 25%, to $1.59, Friday and are up about 8% this year.The maker of the CyPath lung cancer test said it agreed to sell 2.05 million shares for $1.30 each. The private placement includes 2.66 million warrants with an exercise price of $1.50 a share.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2476262758","title":"BioAffinity Technologies announces pricing of $2.66M registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2476262758","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476262758?lang=en_us&edition=fundamental","pubTime":"2024-10-19 00:52","pubTimestamp":1729270332,"startTime":"0","endTime":"0","summary":"BioAffinity Technologies (BIAF) announced it has entered into a securities purchase agreement with institutional investors for the purchase and sal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-announces-pricing-of-2-66m-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-announces-pricing-of-2-66m-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2476513262","title":"bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2476513262","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476513262?lang=en_us&edition=fundamental","pubTime":"2024-10-19 00:45","pubTimestamp":1729269900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241018:nTUABZJJC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIAF","BIAFW"],"gpt_icon":0},{"id":"2476567267","title":"bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2476567267","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476567267?lang=en_us&edition=fundamental","pubTime":"2024-10-19 00:45","pubTimestamp":1729269900,"startTime":"0","endTime":"0","summary":"SAN ANTONIO, October 18, 2024----bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 2,048,294 shares  of common stock in a registered direct offering at a price of $1.30 per share and, in a concurrent private placement, common warrants  to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share. The Warrants are initially exercisable on the date that the Company’s stockholders approve the exercise of the Warrants and the issuance of the shares upon exercise thereof and will expire five years from the date of such approval.This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale wou","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/q6Q3zMZsAWniz8QY0t55Vg--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8f16fd44840f77e59034a2c7341a4589","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/q6Q3zMZsAWniz8QY0t55Vg--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8f16fd44840f77e59034a2c7341a4589"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-announces-pricing-2-164500231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIAF","BIAFW","BK4139"],"gpt_icon":1},{"id":"2475488839","title":"bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2475488839","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475488839?lang=en_us&edition=fundamental","pubTime":"2024-10-16 20:00","pubTimestamp":1729080000,"startTime":"0","endTime":"0","summary":"bioAffinity VP served on expert panel that published new guidance. SAN ANTONIO, October 16, 2024----bioAffinity Technologies’  Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the peer-reviewed paper, \"Implementation of flow cytometry testing on rare matrix samples: Special considerations and best practices when the sample is unique or difficult to obtain,\" in the journal Cytometry Part B: Clinical Cytometry, the official journal of the International Clinical Cytometry Society.\"Our CyPath Lung noninvasive test for the early detection of lung cancer is a novel test that uses sputum, a unique sample type that is not typically used in clinical flow cytometry assays,\" Rebeles said. Flow cytometry is a well-established technology used in both research and clinical practice because of its ability to rapidly measure physical and chemical properties of cells in biological samples.The paper supplements the Clinical and Laboratory St","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cwznP88cncaX6u4lv6JPkw--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/80725cf367b990b8f8a0f7986d229c9c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cwznP88cncaX6u4lv6JPkw--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/80725cf367b990b8f8a0f7986d229c9c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-cypath-lung-cancer-test-120000606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIAFW","BIAF","BK4139"],"gpt_icon":0},{"id":"2474720372","title":"BioAffinity Technologies Appoints J. Michael Edwards as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2474720372","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474720372?lang=en_us&edition=fundamental","pubTime":"2024-10-11 02:10","pubTimestamp":1728583816,"startTime":"0","endTime":"0","summary":"BioAffinity Technologies  said Thursday it named J. Michael Edwards as chief financial officer, effective Nov. 5.The biotechnology company said Edwards has been serving as interim CFO since Sept. 15 and previously was the company's consulting CFO from 2014 to 2023. He also oversaw BioAffinity's initial public offering in 2022, the company said.BIAF shares were down 4.5% in recent trading.Price: 1.90, Change: -0.09, Percent Change: -4.52","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2474173097","title":"bioAffinity Technologies names J. Michael Edwards as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2474173097","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474173097?lang=en_us&edition=fundamental","pubTime":"2024-10-10 20:19","pubTimestamp":1728562783,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies  Thursday said thatJ. Michael Edwards has accepted the position of Chief Financial Officer.Edwards has been bioAffinity’s interim CFO since Sept. 15 and previously served as bioAffinity’s consulting CFO from 2014 to 2023, overseeing the company’s initial public offering in 2022. Edwards will report directly to bioAffinity Technologies President and CEO Maria Zannes.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1659825850/image_1659825850.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1659825850/image_1659825850.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4157534-bioaffinity-technologies-names-j-michael-edwards-as-cfo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2474714458","title":"bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2474714458","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474714458?lang=en_us&edition=fundamental","pubTime":"2024-10-10 20:00","pubTimestamp":1728561603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241010:nTUA47ZF8D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2474712181","title":"bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2474712181","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474712181?lang=en_us&edition=fundamental","pubTime":"2024-10-10 20:00","pubTimestamp":1728561600,"startTime":"0","endTime":"0","summary":"Edwards rejoins the Company after serving as interim CFO. Edwards will report directly to bioAffinity Technologies President and CEO Maria Zannes. \"We are delighted to welcome Michael back to our executive leadership team. He was key to our successful IPO and instrumental in setting up the financial infrastructure and internal controls of our public company,\" Zannes said. \"His experience and deep familiarity with bioAffinity make him the ideal CFO to oversee the long-term financial and strategic direction of the Company, including the ongoing commercialization of CyPath Lung.\". \"I am very pleased to rejoin bioAffinity as we bring CyPath Lung to market,\" Edwards said. \"I look forward to leveraging my experience to provide responsible stewardship and operational excellence, with a steadfast commitment to ethics and safety. As the company enters this pivotal commercialization stage, I look forward to collaborating with the team to drive long-term growth, build shareholder value, and ultim","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3a7hjw6mbjvgf_JHXu5kpw--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/550dd8285d0042b2d56f62f5072bc986","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3a7hjw6mbjvgf_JHXu5kpw--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/550dd8285d0042b2d56f62f5072bc986"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-names-j-michael-120000695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPO","BIAFW","BK4139","BIAF","CFO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioaffinitytech.com;ir.bioaffinitytech.com","stockEarnings":[{"period":"1week","weight":0.0222},{"period":"1month","weight":-0.2418},{"period":"3month","weight":-0.2333},{"period":"6month","weight":-0.3333},{"period":"1year","weight":-0.023},{"period":"ytd","weight":-0.0615}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.","exchange":"NASDAQ","name":"bioAffinity Technologies, Inc.","nameEN":"bioAffinity Technologies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest bioAffinity Technologies, Inc.(BIAF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"bioAffinity Technologies, Inc.,BIAF,bioAffinity Technologies, Inc.股票,bioAffinity Technologies, Inc.股票老虎,bioAffinity Technologies, Inc.股票老虎国际,bioAffinity Technologies, Inc.行情,bioAffinity Technologies, Inc.股票行情,bioAffinity Technologies, Inc.股价,bioAffinity Technologies, Inc.股市,bioAffinity Technologies, Inc.股票价格,bioAffinity Technologies, Inc.股票交易,bioAffinity Technologies, Inc.股票购买,bioAffinity Technologies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest bioAffinity Technologies, Inc.(BIAF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction